Shares in Trellus Health PLC (AIM:TRLS) soared 180% after the company announced a collaboration with Johnson & Johnson (NYSE:JNJ) Health Care Systems Inc.
The partnership will pilot Trellus Health’s digital platform, Trellus Elevate, in the US to support patients with moderate to severe inflammatory bowel disease (IBD).
Under the agreement, Trellus will receive an upfront licensing fee and a fixed monthly management fee during the one-year trial.
The platform integrates data analytics with personalised resilience programs, aiming to help patients manage the emotional and physical challenges of chronic conditions, adhere to treatment plans, and take control of their health.
Eligible patients prescribed Johnson & Johnson therapies will gain access to Trellus Elevate as part of the pharmaceutical company’s patient support programmes.
In the first hour of trading the stock was changing hands for 1.68p, up 1.08p.